These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25994861)

  • 1. Cruzipain: An Update on its Potential as Chemotherapy Target against the Human Pathogen Trypanosoma cruzi.
    Branquinha MH; Oliveira SS; Sangenito LS; Sodre CL; Kneipp LF; d'Avila-Levy CM; Santos AL
    Curr Med Chem; 2015; 22(18):2225-35. PubMed ID: 25994861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel scaffolds for inhibition of Cruzipain identified from high-throughput screening of anti-kinetoplastid chemical boxes.
    Salas-Sarduy E; Landaburu LU; Karpiak J; Madauss KP; Cazzulo JJ; Agüero F; Alvarez VE
    Sci Rep; 2017 Sep; 7(1):12073. PubMed ID: 28935948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent and Selective Inhibitors of Trypanosoma cruzi Triosephosphate Isomerase with Concomitant Inhibition of Cruzipain: Inhibition of Parasite Growth through Multitarget Activity.
    Aguilera E; Varela J; Birriel E; Serna E; Torres S; Yaluff G; de Bilbao NV; Aguirre-López B; Cabrera N; Díaz Mazariegos S; de Gómez-Puyou MT; Gómez-Puyou A; Pérez-Montfort R; Minini L; Merlino A; Cerecetto H; González M; Alvarez G
    ChemMedChem; 2016 Jun; 11(12):1328-38. PubMed ID: 26492824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of levothyroxine antichagasic activity through computer-aided drug repurposing.
    Bellera CL; Balcazar DE; Alberca L; Labriola CA; Talevi A; Carrillo C
    ScientificWorldJournal; 2014; 2014():279618. PubMed ID: 24592161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cruzipain Activates Latent TGF-β from Host Cells during T. cruzi Invasion.
    Ferrão PM; d'Avila-Levy CM; Araujo-Jorge TC; Degrave WM; Gonçalves Ada S; Garzoni LR; Lima AP; Feige JJ; Bailly S; Mendonça-Lima L; Waghabi MC
    PLoS One; 2015; 10(5):e0124832. PubMed ID: 25938232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The major cysteine proteinase of Trypanosoma cruzi: a valid target for chemotherapy of Chagas disease.
    Jose Cazzulo J; Stoka V; Turk V
    Curr Pharm Des; 2001 Aug; 7(12):1143-56. PubMed ID: 11472258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Widespread Anti-Protozoal Action of HIV Aspartic Peptidase Inhibitors: Focus on Plasmodium spp., Leishmania spp. and Trypanosoma cruzi.
    Santos AL; d'Avila-Levy CM; Kneipp LF; Sodré CL; Sangenito LS; Branquinha MH
    Curr Top Med Chem; 2017; 17(11):1303-1317. PubMed ID: 27784256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of N-myristoyltransferase as Potential Chemotherapeutic Target in Mammal-Dwelling Stages of Trypanosoma cruzi.
    Herrera LJ; Brand S; Santos A; Nohara LL; Harrison J; Norcross NR; Thompson S; Smith V; Lema C; Varela-Ramirez A; Gilbert IH; Almeida IC; Maldonado RA
    PLoS Negl Trop Dis; 2016 Apr; 10(4):e0004540. PubMed ID: 27128971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inhibitors.
    Lima AP; dos Reis FC; Serveau C; Lalmanach G; Juliano L; Ménard R; Vernet T; Thomas DY; Storer AC; Scharfstein J
    Mol Biochem Parasitol; 2001 Apr; 114(1):41-52. PubMed ID: 11356512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cruzipain, the major cysteine proteinase from the protozoan parasite Trypanosoma cruzi.
    Cazzulo JJ; Stoka V; Turk V
    Biol Chem; 1997 Jan; 378(1):1-10. PubMed ID: 9049059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of a series of alpha-pyrone derivatives against Leishmania (L.) infantum and Trypanosoma cruzi.
    Tempone AG; Ferreira DD; Lima ML; Costa Silva TA; Borborema SET; Reimão JQ; Galuppo MK; Guerra JM; Russell AJ; Wynne GM; Lai RYL; Cadelis MM; Copp BR
    Eur J Med Chem; 2017 Oct; 139():947-960. PubMed ID: 28881289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activity against Trypanosoma cruzi of substituted 1,4-naphthoquinones.
    Olímpio da Silva A; da Silva Lopes R; Vieira de Lima R; Santos Suniga Tozatti C; Marques MR; de Albuquerque S; Beatriz A; Pires de Lima D
    Eur J Med Chem; 2013 Feb; 60():51-6. PubMed ID: 23279867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period.
    Duschak VG
    Recent Pat Antiinfect Drug Discov; 2016; 11(2):74-173. PubMed ID: 27784230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease.
    Gaspar L; Coron RP; KongThoo Lin P; Costa DM; Perez-Cabezas B; Tavares J; Roura-Ferrer M; Ramos I; Ronin C; Major LL; Ciesielski F; Pemberton IK; MacDougall J; Ciapetti P; Smith TK; Cordeiro-da-Silva A
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006180. PubMed ID: 29357372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Genetic Validation of Chemotherapeutic Targets for Chagas' Disease.
    Osorio-Méndez JF; Cevallos AM
    Front Cell Infect Microbiol; 2018; 8():439. PubMed ID: 30666299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered expression of cruzipain and a cathepsin B-like target in a Trypanosoma cruzi cell line displaying resistance to synthetic inhibitors of cysteine-proteinases.
    Yong V; Schmitz V; Vannier-Santos MA; de Lima AP; Lalmanach G; Juliano L; Gauthier F; Scharfstein J
    Mol Biochem Parasitol; 2000 Jun; 109(1):47-59. PubMed ID: 10924756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The crystal structure of cruzain: a therapeutic target for Chagas' disease.
    McGrath ME; Eakin AE; Engel JC; McKerrow JH; Craik CS; Fletterick RJ
    J Mol Biol; 1995 Mar; 247(2):251-9. PubMed ID: 7707373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human T cell responses against the major cysteine proteinase (cruzipain) of Trypanosoma cruzi: role of the multifunctional alpha 2-macroglobulin receptor in antigen presentation by monocytes.
    Morrot A; Strickland DK; Higuchi Mde L; Reis M; Pedrosa R; Scharfstein J
    Int Immunol; 1997 Jun; 9(6):825-34. PubMed ID: 9199965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and anti-Trypanosoma cruzi activity of derivatives from nor-lapachones and lapachones.
    da Silva Júnior EN; de Souza MC; Fernandes MC; Menna-Barreto RF; Pinto Mdo C; de Assis Lopes F; de Simone CA; Andrade CK; Pinto AV; Ferreira VF; de Castro SL
    Bioorg Med Chem; 2008 May; 16(9):5030-8. PubMed ID: 18378461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic targets for drug design against Trypanosoma cruzi, advances and perspectives.
    Rivera G; Bocanegra-García V; Ordaz-Pichardo C; Nogueda-Torres B; Monge A
    Curr Med Chem; 2009; 16(25):3286-93. PubMed ID: 19548870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.